Cipla's subsidiary to acquire US-based Avenue Therapeutics for $ 215 million

At the second stage, InvaGen or its affiliates will acquire the remaining shares of Avenue's common stock, for up to USD 180 million in the aggregate.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2Q2lrCR
via IFTTT